These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27615411)

  • 1. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.
    Li T; Guo L; Chen Z; Gu L; Sun F; Tan X; Chen S; Wang X; Ye S
    Sci Rep; 2016 Sep; 6():33226. PubMed ID: 27615411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.
    Ye S; Chen XX; Lu XY; Wu MF; Deng Y; Huang WQ; Guo Q; Yang CD; Gu YY; Bao CD; Chen SL
    Clin Rheumatol; 2007 Oct; 26(10):1647-54. PubMed ID: 17308858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.
    Go DJ; Park JK; Kang EH; Kwon HM; Lee YJ; Song YW; Lee EB
    Rheumatol Int; 2016 Jan; 36(1):125-31. PubMed ID: 26223808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients.
    Zou J; Guo Q; Chi J; Wu H; Bao C
    Clin Rheumatol; 2015 Apr; 34(4):707-14. PubMed ID: 25609178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis.
    Mukae H; Ishimoto H; Sakamoto N; Hara S; Kakugawa T; Nakayama S; Ishimatsu Y; Kawakami A; Eguchi K; Kohno S
    Chest; 2009 Nov; 136(5):1341-1347. PubMed ID: 19581351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
    Ikeda S; Arita M; Morita M; Ikeo S; Ito A; Tokioka F; Noyama M; Misaki K; Notohara K; Ishida T
    BMC Pulm Med; 2015 Dec; 15():159. PubMed ID: 26651481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease.
    Nara M; Komatsuda A; Omokawa A; Togashi M; Okuyama S; Sawada K; Wakui H
    Mod Rheumatol; 2014 Jul; 24(4):633-6. PubMed ID: 24252021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.
    Johnson C; Pinal-Fernandez I; Parikh R; Paik J; Albayda J; Mammen AL; Christopher-Stine L; Danoff S
    Lung; 2016 Oct; 194(5):733-7. PubMed ID: 27166633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
    Gil B; Merav L; Pnina L; Chagai G
    Clin Rheumatol; 2016 Aug; 35(8):2125-2130. PubMed ID: 25846833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
    Khanna D; Albera C; Fischer A; Khalidi N; Raghu G; Chung L; Chen D; Schiopu E; Tagliaferri M; Seibold JR; Gorina E
    J Rheumatol; 2016 Sep; 43(9):1672-9. PubMed ID: 27370878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
    Takada T; Aoki A; Asakawa K; Sakagami T; Moriyama H; Narita I; Sato S
    Respir Med; 2015 Sep; 109(9):1174-80. PubMed ID: 26187000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases.
    Fujisawa T; Hozumi H; Kono M; Enomoto N; Nakamura Y; Inui N; Nakashima R; Imura Y; Mimori T; Suda T
    Respir Investig; 2017 Mar; 55(2):130-137. PubMed ID: 28274528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients.
    Sun Y; Liu Y; Yan B; Shi G
    Rheumatol Int; 2013 May; 33(5):1295-302. PubMed ID: 23143553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
    Xu Y; Yang CS; Li YJ; Liu XD; Wang JN; Zhao Q; Xiao WG; Yang PT
    Clin Rheumatol; 2016 Jan; 35(1):113-6. PubMed ID: 26660480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myofascia-dominant involvement on whole-body MRI as a risk factor for rapidly progressive interstitial lung disease in dermatomyositis.
    Karino K; Kono M; Kono M; Sakamoto K; Fujieda Y; Kato M; Amengual O; Oku K; Yasuda S; Atsumi T
    Rheumatology (Oxford); 2020 Jul; 59(7):1734-1742. PubMed ID: 31925431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies.
    Sato S; Kuwana M; Fujita T; Suzuki Y
    Mod Rheumatol; 2012 Aug; 22(4):625-9. PubMed ID: 22124544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical experience of pirfenidone based on corticosteroids and immunosuppressant treatment for interstitial pneumonia with autoimmune features].
    Huang H; Sun YX; Li S; Shao C; Xu K; Xu ZJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Sep; 42(9):700-704. PubMed ID: 31484245
    [No Abstract]   [Full Text] [Related]  

  • 19. Mortality Risk Prediction in Amyopathic Dermatomyositis Associated With Interstitial Lung Disease: The FLAIR Model.
    Lian X; Zou J; Guo Q; Chen S; Lu L; Wang R; Zhou M; Fu Q; Ye Y; Bao C
    Chest; 2020 Oct; 158(4):1535-1545. PubMed ID: 32428508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
    Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
    Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.